No-profit pricing in the poorest countries


Significantly reduced pricing for HIV medicines help people in need receive proper treatment


In resource-limited countries, the cost of medicines and diagnostics is one of many barriers to medical care. These countries can also be the hardest hit by diseases such as HIV/AIDS. In fact, low- and middle-income countries defined by the World Bank as developing economies, including sub-Saharan Africa, are home to 87% of all people living with HIV/AIDS.

What we’re doing

We are committed to increasing access to HIV healthcare globally by developing sustainable healthcare solutions, particularly for people living in low- and middle-income countries.

We supply our second-line protease inhibitor Invirase (saquinavir) for treating HIV/AIDS at no-profit prices to least developed countries and to sub-Saharan Africa. In this way, our HIV medicine is available in 63 countries that are home to 64% of all people living with HIV/AIDS.

Our prices in these countries are the lowest at which HIV medicines can be viably and sustainably sold by us: they do not reflect costs for research and development, marketing, distribution or overhead. We review our no-profit prices annually and adjust them when necessary to ensure they remain no-profit.

We also supply Invirase at significantly reduced prices in lower middle-income countries, where HIV/AIDS is a growing problem.

Since 2007, we have provided Valcyte (valganciclovir), our oral medication for treating AIDS-related cytomegalovirus retinitis (CMVR), at reduced prices for AIDS treatment programmes led by non-governmental organisations in low- and middle-income countries and in sub-Saharan Africa. In 2013, through a purchase agreement with the Medicines Patent Pool, we further reduced the price for Valcyte for use in HIV patients, making it 90% cheaper for 138 developing countries, including a number of upper middle-income countries such as India and China.

Through our AmpliCare initiative we offer our diagnostic HIV tests at substantially reduced prices. In this way, we are helping increase access to the latest equipment for early detection of HIV infection in infants and reliable monitoring of HIV treatment efficacy.

Our impact

We are addressing affordability with plans that offer prices similar to or below those of generic medicines for 87% of people living with HIV/AIDS worldwide.

Terms and conditions

Invirase prices effective as of 1 February 2012, Valcyte price as of 5 August 2013.

Prices applicable to all orders from eligible countries, and are subject to the conditions that the drug will not be diverted or re-exported to countries not qualifying for the specified price.

All purchasers placing orders for reduced-priced HIV medicines from Roche Basel will be required to provide the final delivery destination and recipient name in order to enable tracking and monitoring of product supply.

More stories

Tags: Access to healthcare, Africa